Eli Lilly Muted As Arthritis Drug Fails Goals In Covid-19 Patients By Investing.com

Eli Lilly Muted As Arthritis Drug Fails Goals In Covid-19 Patients By Investing.com


© Reuters

By Dhirendra Tripathi

Investing.com – Shares of Eli Lilly (NYSE:) were marginally negative as the company’s announcement that the phase 3 study of a drug for treating rheumatoid arthritis in Covid-19 patients had failed to meet its goals left traders disappointed.

Eli’s filing said patients treated with baricitinib were 2.7% less likely than those receiving standard of care to progress to ventilation or death, a difference found to be statistically insignificant.

Baricitinib is approved in the U.S. as a treatment for adults with moderate to severe rheumatoid arthritis and in the EU and Japan for treating atopic dermatitis.

Additional research is ongoing to further evaluate the potential role of baricitinib in Covid-19, the company said.

The pharmaceutical giant will share the data from the study with regulatory authorities in the U.S., the E.U. and other geographies to evaluate next steps for baricitinib.

 

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





Source link

Leave a comment

Send a Comment

Your email address will not be published. Required fields are marked *